Unique ID issued by UMIN | UMIN000037054 |
---|---|
Receipt number | R000042222 |
Scientific Title | The study of efficacy of lenvatinib in patients with hepatocellular carcinoma(HCC): Multicenter analysis. |
Date of disclosure of the study information | 2019/06/13 |
Last modified on | 2019/06/13 15:53:12 |
The study of efficacy of lenvatinib in patients with hepatocellular carcinoma(HCC): Multicenter analysis.
The study of efficacy of lenvatinib in patients with hepatocellular carcinoma(HCC): Multicenter analysis.
The study of efficacy of lenvatinib in patients with hepatocellular carcinoma(HCC): Multicenter analysis.
The study of efficacy of lenvatinib in patients with hepatocellular carcinoma(HCC): Multicenter analysis.
Japan |
Hepatocellular carcinoma
Hepato-biliary-pancreatic medicine |
Malignancy
NO
The objective of this study is to investigate the prognostic and predictive factors of lenvatinib in patients with HCC.
Safety,Efficacy
OS
PFS
OR/DCR
Safety
Observational
20 | years-old | <= |
90 | years-old | > |
Male and Female
1)At least 20 years old when consent is given
2)Histologically or clinically (imaging and tumor markers) diagnosed hepatocellular carcinoma found to be ineligible for resection or local treatment
3)Lesions measurable with contrast-enhanced CT or contrast-enhanced MRI
4)Child-Pugh class A or B
5)ECOG performance status (PS) of 0 or 1
6) Adequate functional reserve of major organs
7)Capable of complying with requirements about visit days, medication, and laboratory tests
8)The patient has been fully informed and has an adequate understanding about the study and has given voluntary written consent before participation
1)Clinically significant ascites (refractory ascites requiring drainage)
2)Esophageal varices with the potential to bleed
4)Brain tumor
5)On dialysis
6)Gastrointestinal hemorrhage during past month
7)Active multiple cancer
8)Any of the following concurrent diseases:
Grade 3 or greater arrhythmia or poorly controlled hypertension according to the JCOG/JSCO Japanese translation of the NCI Common Terminology Criteria for Adverse Events v 4.0 (CTCAE v 4.0)
9)Orally taking an herbal medicine approved for the treatment of cancer (e.g., shosaikoto)
10)Human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS) related disease
11) Pregnant or nursing
12) Otherwise found ineligible as a subject by the researcher
250
1st name | Makoto |
Middle name | Makoto |
Last name | Chuma |
Yokohama City University Medical Center
Gastroenterological Center
232-0024
Yokohama
045-261-5656
chuma@yokohama-cu.ac.jp
1st name | Makoto |
Middle name | |
Last name | Chuma |
Yokohama City University Medical Center
Gastroenterological Center
232-0024
Yokohama
045-261-5656
chuma@yokohama-cu.ac.jp
Yokohama City University Medical Center
Yokohama City University Medical Center
Self funding
YCU Center for Novel and Exploratory Clinical Trials
1-1-1, Fukuura, Kanazawa-ku, Yokohama
045-370-7991
nextjim1@yokohama-cu.ac.jp
NO
2019 | Year | 06 | Month | 13 | Day |
Unpublished
Open public recruiting
2018 | Year | 05 | Month | 01 | Day |
2018 | Year | 05 | Month | 01 | Day |
2018 | Year | 05 | Month | 01 | Day |
2025 | Year | 03 | Month | 31 | Day |
retrospective observational study
2019 | Year | 06 | Month | 13 | Day |
2019 | Year | 06 | Month | 13 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042222